Mereo Biopharma Group Plc

Research Mereo Biopharma Group Plc (MREO) on Bullrun: market cap USD 52.96M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerMREO
• ExchangeNASDAQ
• CountryUnited Kingdom
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 52.96M
• Financial periodFY2025
• RevenueUSD 500.00K
• Net incomeUSD 41.88M
• Free cash flow-USD 30.99M

Valuation Snapshot

latest market cap is USD 52.96M.

About Mereo Biopharma Group Plc

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2.

Frequently asked questions

What is Mereo Biopharma Group Plc's market cap?

Mereo Biopharma Group Plc's market capitalization is USD 52.96M.

What does Mereo Biopharma Group Plc do?

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta;